Top Biotech Picks For 2021 With The Most Upside Potential
In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that…
In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that…
For bullish biotech investors looking for a way to play the sector well into 2021, today’s article highlights an ETF to consider for that purpose,…
From traditional “Big Pharma” stocks that have adopted (or are adopting) a greater focus on biotech to large “pure-play” biotech companies to “emerging” biotech stocks…
The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors…
October has seen the FDA approve the first drug for COVID-19 (remdesivir), the first treatment for Ebola virus (Regeneron Pharmaceuticals’ Inmazeb), and the first drug…
When it comes to the seven “unhealthy” biotech stocks that are the focus of today’s article, the author advises the following: “While these aren’t terrible…
“Biotech stocks are breaking out,” declares the author of today’s article. When it comes to playing this breakout, however, he advises that the obvious play…
“Imagine the market for an influenza vaccine that would not require modifications each year to address annual mutations in the influenza virus, that brings about…
“The upside in biotech sector has been led by the small companies, primarily the ones developing a vaccine for coronavirus,” notes the author of today’s…
“With coronavirus cases climbing in the U.S., this is likely going to be a clear focus for quite some time,” declares the author of today’s…